<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Valanti, E. K.</style></author><author><style face="normal" font="default" size="100%">Dalakoura-Karagkouni, K.</style></author><author><style face="normal" font="default" size="100%">Siasos, G.</style></author><author><style face="normal" font="default" size="100%">Kardassis, D.</style></author><author><style face="normal" font="default" size="100%">Eliopoulos, A. G.</style></author><author><style face="normal" font="default" size="100%">Sanoudou, D.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Advances in biological therapies for dyslipidemias and atherosclerosis</style></title><secondary-title><style face="normal" font="default" size="100%">MetabolismMetabolismMetabolism</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Metabolism: clinical and experimental</style></alt-title><short-title><style face="normal" font="default" size="100%">Metabolism: clinical and experimentalMetabolism: clinical and experimental</style></short-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Animals</style></keyword><keyword><style  face="normal" font="default" size="100%">Atherosclerosis/epidemiology/*therapy</style></keyword><keyword><style  face="normal" font="default" size="100%">Biological Therapy/methods/*trends</style></keyword><keyword><style  face="normal" font="default" size="100%">Dyslipidemias/epidemiology/*therapy</style></keyword><keyword><style  face="normal" font="default" size="100%">Endocrinology/methods/trends</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Therapies, Investigational/methods/trends</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">116</style></volume><pages><style face="normal" font="default" size="100%">154461</style></pages><isbn><style face="normal" font="default" size="100%">1532-8600 (Electronic)0026-0495 (Linking)</style></isbn><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Atherosclerosis is a multifactorial disease influenced by genetics, lifestyle and environmental factors. Despite therapeutic advances that reduce the risk of cardiovascular events, atherosclerosis-related diseases remain the leading cause of mortality worldwide. Precise targeting of genes involved in lipoprotein metabolism is an emerging approach for atherosclerosis prevention and treatment. This article focuses on the latest developments, clinical potential and current challenges of monoclonal antibodies, vaccines and genome/transcriptome modification strategies, including antisense oligonucleotides, genome/base editing and gene therapy. Multiple lipid lowering biological therapies have already been approved by the FDA with impressive results to date, while many more promising targets are being pursued in clinical trials or pre-clinical animal models.</style></abstract><accession-num><style face="normal" font="default" size="100%">33290761</style></accession-num><notes><style face="normal" font="default" size="100%">Valanti, Eftaxia-KonstantinaDalakoura-Karagkouni, KaterinaSiasos, GerasimosKardassis, DimitrisEliopoulos, Aristides GSanoudou, DespinaengResearch Support, Non-U.S. Gov'tReview2020/12/09 06:00Metabolism. 2021 Mar;116:154461. doi: 10.1016/j.metabol.2020.154461. Epub 2020 Dec 5.</style></notes><auth-address><style face="normal" font="default" size="100%">4th Department of Internal Medicine, Clinical Genomics and Pharmacogenomics Unit, 'Attikon' Hospital, Medical School, National and Kapodistrian University of Athens, Greece; Molecular Biology Division, Biomedical Research Foundation of the Academy of Athens, Greece; Center for New Biotechnologies and Precision Medicine, Medical School, National and Kapodistrian University of Athens, Athens, Greece.Laboratory of Biochemistry, University of Crete Medical School Heraklion, Greece.First Department of Cardiology, Hippokration Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.Laboratory of Biochemistry, University of Crete Medical School Heraklion, Greece; Division of Gene Regulation and Genomics, Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology of Hellas, Heraklion, Greece.Molecular Biology Division, Biomedical Research Foundation of the Academy of Athens, Greece; Center for New Biotechnologies and Precision Medicine, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Biology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.4th Department of Internal Medicine, Clinical Genomics and Pharmacogenomics Unit, 'Attikon' Hospital, Medical School, National and Kapodistrian University of Athens, Greece; Molecular Biology Division, Biomedical Research Foundation of the Academy of Athens, Greece; Center for New Biotechnologies and Precision Medicine, Medical School, National and Kapodistrian University of Athens, Athens, Greece. Electronic address: dsanoudou@med.uoa.gr.</style></auth-address></record></records></xml>